Management tracks: Achillion, Navidea

Rare disease company Achillion Pharmaceuticals Inc. (NASDAQ:ACHN) hired Anthony Gibney as EVP and CBO. He was managing director and co-head of the biotechnology investment banking team at Leerink Partners.

Immunotherapy company Navidea Biopharmaceuticals Inc. (NYSE-A:NAVB; Tel Aviv:NAVB) said CEO Michael Goldberg has resigned to become CEO of the immunotherapy company's Macrophage Therapeutics Inc. subsidiary. During a conference call Thursday, Navidea said it is mulling a spin out of the subsidiary. Goldberg will focus on progressing Macrophage's preclinical orphan disease pipeline and addressing its long-term funding needs. CFO and COO Jed Latkin will serve as Navidea's interim CEO...